CEO of NDA Partners, Eric Poissontoday announced that David Wurtman, MD, MBA, an experienced business executive and product development expert, joined the company as an expert consultant. Dr. Wurtman was previously chief executive of Lyric Pharmaceuticals, a critical care therapy development company, and medical director of Lucid Diagnostics.
WASHINGTON, June 23, 2022 /PRNewswire-PRWeb/ — Managing Director of NDA Partners, Eric Poissontoday announced that David WurtmanMD, MBA, an experienced business leader and expert in product development, joined the company as an Expert Consultant. Dr. Wurtman joined the firm to support companies in corporate strategy, fundraising, mergers and acquisitions, business development and licensing, product development, market research, positioning product and clinical and regulatory strategy and development. He has particular expertise in assisting emerging companies and in starting up products and platforms.
Dr. Wurtman served as CEO of Lyric Pharmaceuticals, a critical care therapy development company which he successfully founded, built and financed, and Chief Marketing Officer of Lucid Diagnostics, a medical device company which went public via a public offering. initial (IPO) in 2021. He has advised more than 25 biopharmaceutical, technology platform, medical device, diagnostic and health informatics companies and has led or advised approximately 25 transactions and raised more than $70 million from the venture capital, private equity, the Family Office and the US government. He has deep expertise in drug, biologics and diagnostic device development and has led successful interactions with the FDA, including obtaining FDA Breakthrough Designation.
Dr. Wurtman is a Board Certified Physician in Internal Medicine and in addition to his roles at Lyric and Lucid, he has also held corporate, business and product development roles at Genzyme, Protein Design Labs, Eos Biotechnology, Kineta and Ansun Biopharma.
According dr. Alberto GutierrezHead of NDA Partners’ Diagnostic Devices Practice, “Dr. Wurtman brings valuable experience in business development, product development, and helping to build and lead development teams for diagnostics companies. early-stage drugs, biologics and diagnostic devices. We are delighted to welcome him to NDA Partners.”
dr. David Wurtman obtained his medical degree from Harvard Medical School and MBA from MIT Sloan School of Management. He completed his residency in internal medicine at Mount Auburn, a Harvard University Hospital, and fellowships with Ben Gurion University of the Negev, Israel and the Department of Hormone Research, Weizmann Institute, Israel.
About NDA Partners
NDA Partners, a ProPharma Group company, is a life science management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology and medical device industries worldwide. entire. NDA Partners’ highly experienced expert consultants include three former FDA Center Directors; former CEO and Scientific Director of the United States Pharmacopeial Convention (USP); an international team of more than 100 former senior executives from the pharmaceutical industry and regulatory agencies; and an extensive roster of highly skilled experts in specialist areas including non-clinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions and management of development programs. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management. .
Eric PoissonGeneral director
Eric PoissonNDA Partners, 540-738-2550, FishEric@ndapartners.com
SOURCE NDA Partners